IL155367A0 - NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES - Google Patents

NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES

Info

Publication number: IL155367A0
Authority: IL; Israel
Prior art keywords: preparation; trisubstituted; pyrido; pyrimidin; compounds
Prior art date: 2000-10-23

Application number

IL15536701A

Other languages

English (en)

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-23

Filing date

2001-10-23

Publication date

2003-12-23

2001-10-23 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2003-12-23 Publication of IL155367A0 publication Critical patent/IL155367A0/xx

Links

102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 title abstract 4
108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 title abstract 2
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000003814 drug Substances 0.000 title 1
230000001404 mediated effect Effects 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
-1 2,4,8-trisubstituted -8H-pyrido[2,3-d]pyrimidin-7-one compounds Chemical class 0.000 abstract 1
229940043355 kinase inhibitor Drugs 0.000 abstract 1
239000000203 mixture Chemical class 0.000 abstract 1
239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Virology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Immunology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)

IL15536701A 2000-10-23 2001-10-23 NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES IL155367A0 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US24246100P	2000-10-23	2000-10-23
US31034901P	2001-08-06	2001-08-06
US32661801P	2001-10-02	2001-10-02
PCT/US2001/050493 WO2002059083A2 (fr)	2000-10-23	2001-10-23	Nouveaux composes

Publications (1)

Publication Number	Publication Date
IL155367A0 true IL155367A0 (en)	2003-12-23

Family

ID=27399571

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
IL15536701A IL155367A0 (en)	2000-10-23	2001-10-23	NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES
IL155367A IL155367A (en)	2000-10-23	2003-04-10	2,4,8-TRISUBSTITUTED-8H- PYRIDO[2,3-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/P38 KINASE MEDIATED DISEASES
IL192338A IL192338A0 (en)	2000-10-23	2008-06-19	NOVEL 2,4,8-TRISUBSTITUTED-8h- PYRIDO[2,3-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES
IL192337A IL192337A0 (en)	2000-10-23	2008-06-19	NOVEL 2,4,8-TRISUBSTITUTED-8h- PYRIDO[2,3-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES
IL192339A IL192339A0 (en)	2000-10-23	2008-06-19	NOVEL 2,4,8-TRISUBSTITUTED-8H- PYRIDO[2,3-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/P38 KINASE MEDIATED DISEASES

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
IL155367A IL155367A (en)	2000-10-23	2003-04-10	2,4,8-TRISUBSTITUTED-8H- PYRIDO[2,3-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/P38 KINASE MEDIATED DISEASES
IL192338A IL192338A0 (en)	2000-10-23	2008-06-19	NOVEL 2,4,8-TRISUBSTITUTED-8h- PYRIDO[2,3-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES
IL192337A IL192337A0 (en)	2000-10-23	2008-06-19	NOVEL 2,4,8-TRISUBSTITUTED-8h- PYRIDO[2,3-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES
IL192339A IL192339A0 (en)	2000-10-23	2008-06-19	NOVEL 2,4,8-TRISUBSTITUTED-8H- PYRIDO[2,3-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/P38 KINASE MEDIATED DISEASES

Country Status (21)

Country	Link
US (8)	US7323472B2 (fr)
EP (2)	EP2404603A1 (fr)
JP (3)	JP4524072B2 (fr)
KR (1)	KR100850812B1 (fr)
CN (2)	CN100525768C (fr)
AT (1)	ATE521353T1 (fr)
AU (1)	AU2002246855B2 (fr)
BR (1)	BR0114829A (fr)
CA (1)	CA2426654C (fr)
CY (1)	CY1112100T1 (fr)
CZ (1)	CZ20031125A3 (fr)
DK (1)	DK1333833T3 (fr)
ES (1)	ES2372028T3 (fr)
HU (1)	HU229471B1 (fr)
IL (5)	IL155367A0 (fr)
MX (1)	MXPA03003612A (fr)
NO (1)	NO326830B1 (fr)
NZ (1)	NZ524806A (fr)
PL (1)	PL362049A1 (fr)
PT (1)	PT1333833E (fr)
WO (1)	WO2002059083A2 (fr)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6858617B2 (en)	1998-05-26	2005-02-22	Smithkline Beecham Corporation	Substituted imidazole compounds
CA2341370A1 (fr) *	1998-08-20	2000-03-02	Smithkline Beecham Corporation	Nouveaux composes de triazole substitues
DE69914357T2 (de)	1998-11-04	2004-11-11	Smithkline Beecham Corp.	Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
JP2003514900A (ja)	1999-11-23	2003-04-22	スミスクライン・ビーチャム・コーポレイション	ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
ATE281439T1 (de)	1999-11-23	2004-11-15	Smithkline Beecham Corp	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
US7235551B2 (en) *	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN100525768C (zh) *	2000-10-23	2009-08-12	史密丝克莱恩比彻姆公司	新化合物
JP2004521892A (ja) *	2000-12-20	2004-07-22	メルク　エンド　カムパニー　インコーポレーテッド	（ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤
ATE375980T1 (de)	2002-02-12	2007-11-15	Smithkline Beecham Corp	Nicotinamide und deren verwendung als p38 inhibitoren
KR20040103972A (ko) *	2002-04-19	2004-12-09	스미스클라인 비참 코포레이션	신규 화합물
MXPA05007485A (es)	2003-01-14	2006-01-30	Arena Pharm Inc	Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
MXPA05011710A (es)	2003-05-05	2006-01-23	Hoffmann La Roche	Derivados de pirimidina con actividad de crf.
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN1560035A (zh) *	2004-03-12	2005-01-05	沈阳药科大学	5－羟基吲哚－3－羧酸脂类衍生物
US7767687B2 (en) *	2004-12-13	2010-08-03	Biogen Idec Ma Inc.	Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
US8017395B2 (en)	2004-12-17	2011-09-13	Lifescan, Inc.	Seeding cells on porous supports
US7842809B2 (en) *	2005-01-24	2010-11-30	Bayer Schering Pharma Ag	Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
MY145343A (en) *	2005-03-25	2012-01-31	Glaxo Group Ltd	Novel compounds
US7423042B2 (en)	2005-03-25	2008-09-09	Glaxo Group Limited	Compounds
US20080096905A1 (en)	2005-03-25	2008-04-24	Glaxo Group Limited	Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
PE20061193A1 (es) *	2005-03-25	2006-12-02	Glaxo Group Ltd	DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
WO2006118914A2 (fr) *	2005-04-29	2006-11-09	Children's Medical Center Corporation	Methodes d'augmentation de la proliferation de cardiomyocytes mammiferes adultes par inhibition de la map-kinase p38
US7723342B2 (en) *	2005-05-17	2010-05-25	Schering Corporation	Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
AU2006202209B2 (en)	2005-05-27	2011-04-14	Lifescan, Inc.	Amniotic fluid derived cells
JP2009500297A (ja) *	2005-06-08	2009-01-08	セントカー・インコーポレーテツド	眼の変性についての細胞療法
PE20100743A1 (es) *	2005-11-15	2010-11-25	Glaxo Group Ltd	Nuevos procedimientos y formulaciones
US20070122448A1 (en) *	2005-11-28	2007-05-31	Alireza Rezania	Compositions and methods to create a vascularized environment for cellular transplantation
AU2007244675A1 (en)	2006-04-28	2007-11-08	Lifescan, Inc.	Differentiation of human embryonic stem cells
US8741643B2 (en)	2006-04-28	2014-06-03	Lifescan, Inc.	Differentiation of pluripotent stem cells to definitive endoderm lineage
US20090318424A1 (en) *	2006-06-16	2009-12-24	Mauro Corsi	Novel compounds
EP2031965A4 (fr) *	2006-06-16	2010-06-30	Glaxo Group Ltd	Nouveaux composés
EP2034838A4 (fr) *	2006-06-16	2012-01-04	Glaxo Group Ltd	Nouveaux composés
EP2050749B1 (fr) *	2006-08-08	2017-11-22	Chugai Seiyaku Kabushiki Kaisha	Derive de pyrimidine comme inhibiteur de la pi3k et son utilisation
GB0621830D0 (en) *	2006-11-02	2006-12-13	Chroma Therapeutics Ltd	Inhibitors of p38 mitogen-activated protein kinase
JO2985B1 (ar)	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
CA2676044C (fr) *	2007-01-30	2019-10-22	University Of Georgia Research Foundation, Inc.	Cellules mesodermiques precoces, une population stable de cellules mesendodermiques qui a une utilite pour la generation de lignees endodermiques et mesodermiques et de cellules migratoires multipotentes (mmc)
EP2559756B1 (fr)	2007-07-01	2019-12-18	Janssen Biotech, Inc.	Culture de cellules souches pluripotentes uniques
US9080145B2 (en) *	2007-07-01	2015-07-14	Lifescan Corporation	Single pluripotent stem cell culture
EP3957716A1 (fr)	2007-07-18	2022-02-23	Janssen Biotech, Inc.	Différenciation de cellules souches embryonnaires humaines
DK2185693T3 (da)	2007-07-31	2019-09-23	Lifescan Inc	Differentiering af humane embryoniske stamceller
CA2954431C (fr)	2007-11-27	2021-08-24	Lifescan, Inc.	Differenciation de cellules souches embryonnaires humaines en cellules pancreatiques
JP5733986B2 (ja)	2008-02-21	2015-06-10	ヤンセンバイオテツク，インコーポレーテツド	細胞の付着、培養、及び剥離のための方法、表面改質されたプレート、並びに組成物
US8623648B2 (en)	2008-04-24	2014-01-07	Janssen Biotech, Inc.	Treatment of pluripotent cells
EP2942392B1 (fr)	2008-06-30	2018-10-03	Janssen Biotech, Inc.	Différenciation de cellules souches pluripotentes
US20110305672A1 (en)	2008-07-25	2011-12-15	University Of Georgia Research Foundation, Inc.	COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
AU2009274517B2 (en)	2008-07-25	2015-03-26	The University Of Georgia Research Foundation, Inc.	Compositions for Mesoderm derived ISL1+ Multipotent cells (IMPs), epicardial progenitor cells (EPCs) and multipotent CXCR4+CD56+ cells (C56Cs) and methods of use
US20100028307A1 (en) *	2008-07-31	2010-02-04	O'neil John J	Pluripotent stem cell differentiation
US9234178B2 (en)	2008-10-31	2016-01-12	Janssen Biotech, Inc.	Differentiation of human pluripotent stem cells
EP2350265B1 (fr)	2008-10-31	2019-04-17	Janssen Biotech, Inc.	Différenciation de cellules souches embryonnaires humaines en la lignée endocrine pancréatique
KR101774546B1 (ko)	2008-11-20	2017-09-04	얀센 바이오테크 인코포레이티드	마이크로-캐리어 상의 만능 줄기 세포 배양
KR101687344B1 (ko) *	2008-11-20	2016-12-16	얀센 바이오테크 인코포레이티드	평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물
AU2009322836B2 (en)	2008-11-25	2013-04-04	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
US20100260825A1 (en) *	2009-04-13	2010-10-14	Nair Madhavan G	Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches
US8785184B2 (en)	2009-07-20	2014-07-22	Janssen Biotech, Inc.	Differentiation of human embryonic stem cells
CN102482643B (zh)	2009-07-20	2016-06-29	詹森生物科技公司	人胚胎干细胞的分化
CN103952372B (zh) *	2009-07-20	2016-10-05	詹森生物科技公司	人胚胎干细胞的分化
PL2494035T3 (pl)	2009-10-29	2018-07-31	Janssen Biotech, Inc.	Pluripotencjalne komórki macierzyste
CN102712902B (zh) *	2009-12-23	2019-01-08	詹森生物科技公司	人胚胎干细胞的分化
SG10201408552YA (en)	2009-12-23	2015-02-27	Janssen Biotech Inc	Differentiation of human embryonic stem cells
PH12012501686A1 (en)	2010-03-01	2020-10-19	Janssen Biotech Inc	Methods for purifying cells derived from pluripotent stem cells
RU2587634C2 (ru)	2010-05-12	2016-06-20	Янссен Байотек, Инк.	Дифференцирование эмбриональных стволовых клеток человека
EA201390060A1 (ru) *	2010-07-09	2013-07-30	Байер Интеллектуэль Проперти Гмбх	Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
KR20190027969A (ko)	2010-08-12	2019-03-15	얀센 바이오테크 인코포레이티드	췌장 내분비 전구 세포를 이용한 당뇨병의 치료
PL2853589T3 (pl)	2010-08-31	2018-05-30	Janssen Biotech, Inc	Różnicowanie ludzkich zarodkowych komórek macierzystych
CN103154237B (zh)	2010-08-31	2016-03-16	詹森生物科技公司	多能干细胞的分化
EP3372672A1 (fr)	2010-08-31	2018-09-12	Janssen Biotech, Inc.	Différenciation de cellules souches embryonnaires humaines
EP3323818A1 (fr)	2010-09-22	2018-05-23	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés
JP6184866B2 (ja) *	2010-10-27	2017-08-23	ウォルターアンドエリザホールインスティテュートオブメディカルリサーチ	新規抗がん剤
JP6139410B2 (ja)	2010-12-02	2017-05-31	テクニオンリサーチアンドディベロップメントファウンデーションリミテッド	角膜細胞の作製方法および該角膜細胞を含む細胞集団
EP2652125B1 (fr)	2010-12-15	2017-04-26	Kadimastem Ltd.	Cellules produisant de l'insuline dérivées de cellules souches pluripotentes
JP6005134B2 (ja)	2011-04-21	2016-10-12	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	フルオロアルキル置換ピラゾロピリジンおよびその使用
FI2794857T3 (fi)	2011-12-22	2026-03-25	Janssen Biotech Inc	Ihmisen alkion kantasolujen erilaistaminen yksittäisiksi hormonaalisiksi insuliinipositiivisiksi soluiksi
DE102012200349A1 (de)	2012-01-11	2013-07-11	Bayer Intellectual Property Gmbh	Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102012200360A1 (de)	2012-01-11	2013-07-11	Bayer Intellectual Property Gmbh	Substituierte Triazine und ihre Verwendung
WO2013131923A1 (fr)	2012-03-06	2013-09-12	Bayer Intellectual Property Gmbh	Azabicyles substitués et leur utilisation
CA2866590A1 (fr)	2012-03-07	2013-09-12	Janssen Biotech, Inc.	Milieux definis pour le developpement et la preservation des cellules souches pluripotentes
EP3450544A1 (fr)	2012-06-08	2019-03-06	Janssen Biotech, Inc.	Différenciation de cellules souches embryonnaires humaines en cellules endodrines pancréatiques
ES2837763T3 (es)	2012-12-31	2021-07-01	Janssen Biotech Inc	Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
DK2938723T3 (da)	2012-12-31	2023-02-20	Janssen Biotech Inc	Differentiering af humane embryonale stamceller til pancreatiske endokrine celler under anvendelse af hb9-regulatorer
US10370644B2 (en)	2012-12-31	2019-08-06	Janssen Biotech, Inc.	Method for making human pluripotent suspension cultures and cells derived therefrom
BR112015015714A2 (pt)	2012-12-31	2017-07-11	Janssen Biotech Inc	suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
MX2015010966A (es)	2013-03-01	2016-04-04	Bayer Pharma AG	Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos.
WO2014159662A1 (fr)	2013-03-13	2014-10-02	University Of Miami	Procédé pour isoler et purifier les microvésicules de surnageants de culture cellulaire et fluides biologiques
US12558316B2 (en)	2013-03-13	2026-02-24	University Of Miami	Methods and compositions for the treatment of epidermolysis bullosa
AP2016008970A0 (en)	2013-07-10	2016-01-31	Bayer Pharma AG	Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
WO2015175307A1 (fr)	2014-05-16	2015-11-19	Janssen Biotech, Inc.	Utilisation de petites molécules pour améliorer l'expression du gène mafa dans des cellules endocrines pancréatiques
PL3242666T3 (pl)	2015-01-06	2025-02-17	Arena Pharmaceuticals, Inc.	Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt)	2015-06-22	2023-12-05	Arena Pharmaceuticals, Inc.	Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
JP6394547B2 (ja) *	2015-09-18	2018-09-26	トヨタ自動車株式会社	車両制御装置
HK1254740A1 (zh)	2015-11-30	2019-07-26	Kadimastem Ltd.	分化和纯化胰腺内分泌细胞的方法
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
US10420803B2 (en)	2016-04-14	2019-09-24	Janssen Biotech, Inc.	Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
GB201611712D0 (en)	2016-07-02	2016-08-17	Hvivo Services Ltd	Methods and compounds for the treatment or prevention of severe or persistent influenza
MX2019009841A (es)	2017-02-16	2020-01-30	Arena Pharm Inc	Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
BR112020006677A2 (pt)	2017-10-05	2020-10-06	Fulcrum Therapeutics, Inc.	uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
GB201721793D0 (en)	2017-12-22	2018-02-07	Hvivo Services Ltd	Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
CA3102136A1 (fr)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methodes de traitement de troubles associes au recepteur s1p1<sb />
TW202112368A (zh)	2019-06-13	2021-04-01	荷蘭商法西歐知識產權股份有限公司	用於治療有關dux4表現之疾病的抑制劑組合
US11697648B2 (en)	2019-11-26	2023-07-11	Theravance Biopharma R&D Ip, Llc	Fused pyrimidine pyridinone compounds as JAK inhibitors
WO2021202990A2 (fr) *	2020-04-03	2021-10-07	TEPPER, Mark, Allan	Méthodes de traitement d'infections à betacoronavirus
AU2021327376A1 (en)	2020-08-21	2023-04-20	University Of Miami	Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells
EP4511045A1 (fr)	2022-04-19	2025-02-26	University of Miami	Compositions avec microvésicules pour la prévention et le traitement de la maladie du greffon contre l'hôte

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2833779A (en)	1956-10-29	1958-05-06	American Cyanamid Co	Substituted pyrazoles
US3910913A (en)	1969-11-04	1975-10-07	American Home Prod	4,5-Diamino-7H-pyrrolo{8 2,3-d{9 pyrimidine derivatives
US3631045A (en)	1969-11-04	1971-12-28	American Home Prod	4 5-diamino-7h-pyrrolo(2 3-d)pyrimidine derivatives
US3725405A (en) *	1970-06-18	1973-04-03	American Home Prod	2,4,7-TRISUBSTITUTED-{8 PYRIDO 2,3-d{9 PYRIMIDINE-6-CARBOXAMIDES
US3795674A (en) *	1970-06-18	1974-03-05	American Home Prod	Certain 2-substituted-4,6-diamino-5-pyrimidinecarboxaldehydes
US3707475A (en)	1970-11-16	1972-12-26	Pfizer	Antiinflammatory imidazoles
US3940486A (en)	1971-05-10	1976-02-24	Ciba-Geigy Corporation	Imidazole derivatives in the treatment of pain
US3929807A (en)	1971-05-10	1975-12-30	Ciba Geigy Corp	2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
CA966134A (en) *	1972-05-05	1975-04-15	Haydn W.R. Williams	1,8-naphthyridine compounds
US4058614A (en)	1973-12-04	1977-11-15	Merck & Co., Inc.	Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en)	1978-08-29	1980-04-22	E. I. Du Pont De Nemours And Company	Antiinflammatory 4,5-diaryl-2-nitroimidazoles
ZA803539B (en) *	1979-06-14	1982-01-27	Wellcome Found	Alkoxybenzylrimidines method for their preparation formulation thereof and their use in medicine
GR75287B (fr)	1980-07-25	1984-07-13	Ciba Geigy Ag
GB2123831B (en)	1981-07-20	1986-01-15	Ciba Geigy Ag	Trisubstituted oxazo compounds
US4503065A (en)	1982-08-03	1985-03-05	E. I. Du Pont De Nemours And Company	Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
JPS60226882A (ja) *	1984-04-24	1985-11-12	Nippon Zoki Pharmaceut Co Ltd	新規ピリミドピリミジン誘導体
US4565875A (en)	1984-06-27	1986-01-21	Fmc Corporation	Imidazole plant growth regulators
US4560691A (en) *	1984-07-13	1985-12-24	Sterling Drug Inc.	5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and preparation
US4686231A (en)	1985-12-12	1987-08-11	Smithkline Beckman Corporation	Inhibition of 5-lipoxygenase products
IL83467A0 (en)	1986-08-15	1988-01-31	Fujisawa Pharmaceutical Co	Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
EP0278686A1 (fr)	1987-02-07	1988-08-17	The Wellcome Foundation Limited	Pyridopyrimidines, leurs procédés de préparation et compositions pharmaceutiques les contenant
JPH01261306A (ja) *	1988-04-13	1989-10-18	Nippon Kayaku Co Ltd	２−アルキルチオ−４−アミノピリミジン誘導体を有効成分とする開花促進剤
BG94957A (bg)	1990-08-10	1993-12-24	Ciba - Geigy Ag	Пиримидинови производни и средство за борба срещу вредители по растенията
FR2665898B1 (fr)	1990-08-20	1994-03-11	Sanofi	Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
IE913473A1 (en) *	1990-10-15	1992-04-22	Fujisawa Pharmaceutical Co	Quinazoline derivatives and their preparation
JPH06502178A (ja)	1990-12-31	1994-03-10	藤沢薬品工業株式会社	イミダゾトリアジン誘導体
JP3375659B2 (ja)	1991-03-28	2003-02-10	テキサスインスツルメンツインコーポレイテツド	静電放電保護回路の形成方法
SG64322A1 (en) *	1991-05-10	1999-04-27	Rhone Poulenc Rorer Int	Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
FR2676734B1 (fr)	1991-05-23	1995-05-19	Roussel Uclaf	Nouveaux derives de la pyrimidine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
IL102764A0 (en)	1991-08-16	1993-01-31	Merck & Co Inc	Quinazoline derivatives,and pharmaceutical compositions containing them
DE4131029A1 (de)	1991-09-18	1993-07-29	Basf Ag	Substituierte pyrido (2,3-d) pyrimidine als antidots
US5716972A (en)	1993-01-13	1998-02-10	Smithkline Beecham Corporation	Pyridyl substituted imidazoles
US5656644A (en)	1994-07-20	1997-08-12	Smithkline Beecham Corporation	Pyridyl imidazoles
US5916891A (en)	1992-01-13	1999-06-29	Smithkline Beecham Corporation	Pyrimidinyl imidazoles
MX9300141A (es)	1992-01-13	1994-07-29	Smithkline Beecham Corp	Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
US6008235A (en)	1992-01-13	1999-12-28	Smithkline Beecham Corporation	Pyridyl substituted imidazoles
GB9303993D0 (en)	1993-02-26	1993-04-14	Fujisawa Pharmaceutical Co	New heterocyclic derivatives
US5466692A (en) *	1993-03-24	1995-11-14	American Home Products Corporation	Substituted pyridopyrimidines and antihypertensives
US5670527A (en)	1993-07-16	1997-09-23	Smithkline Beecham Corporation	Pyridyl imidazole compounds and compositions
US5593992A (en)	1993-07-16	1997-01-14	Smithkline Beecham Corporation	Compounds
US5593991A (en)	1993-07-16	1997-01-14	Adams; Jerry L.	Imidazole compounds, use and process of making
US5869043A (en)	1993-09-17	1999-02-09	Smithkline Beecham Corporation	Drug binding protein
US5783664A (en)	1993-09-17	1998-07-21	Smithkline Beecham Corporation	Cytokine suppressive anit-inflammatory drug binding proteins
CN1048731C (zh)	1993-09-17	2000-01-26	史密丝克莱恩比彻姆公司	编码细胞因子抑制性抗炎药物结合蛋白质的多核苷酸
US5426110A (en) *	1993-10-06	1995-06-20	Eli Lilly And Company	Pyrimidinyl-glutamic acid derivatives
EP0727998B1 (fr)	1993-11-08	2004-01-21	Smithkline Beecham Corporation	Oxazoles pour le traitement de maladies induites par la cytokine
GB9325217D0 (en)	1993-12-09	1994-02-09	Zeneca Ltd	Pyrimidine derivatives
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5559137A (en)	1994-05-16	1996-09-24	Smithkline Beecham Corp.	Compounds
US5547954A (en) *	1994-05-26	1996-08-20	Fmc Corporation	2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US5545669A (en)	1994-06-02	1996-08-13	Adams; Jerry L.	Anti-inflammatory compounds
TW530047B (en)	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
WO1996006843A1 (fr) *	1994-08-29	1996-03-07	Yamanouchi Pharmaceutical Co., Ltd.	Nouveau derive de naphtyridine et composition medicinale a base de ce derive
IL115256A0 (en) *	1994-11-14	1995-12-31	Warner Lambert Co	6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) *	1995-05-03	1997-04-15	Warner-Lambert Company	Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
JPH08325248A (ja) *	1995-05-26	1996-12-10	Chugoku Kayaku Kk	テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法
DE69628175D1 (de)	1995-06-07	2003-06-18	Wyeth Corp	Verfahren zur herstellung von biphenylderivaten
US5760220A (en) *	1995-06-07	1998-06-02	American Home Products Corporation	Process for preparation of biphenyl derivatives
IL118544A (en)	1995-06-07	2001-08-08	Smithkline Beecham Corp	History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en)	1995-06-07	1998-04-14	Smithkline Beecham Corporation	Imidazole compounds and compositions
ZA9610687B (en)	1995-12-22	1997-09-29	Smithkline Beecham Corp	Novel synthesis.
PL187516B1 (pl)	1996-01-11	2004-07-30	Smithkline Beecham Corp	Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki
ZA97175B (en)	1996-01-11	1997-11-04	Smithkline Beecham Corp	Novel substituted imidazole compounds.
US20020137696A1 (en)	1996-01-23	2002-09-26	Robert Tam	Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en)	1996-01-23	2000-11-21	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6372741B1 (en)	1996-03-08	2002-04-16	Smithkline Beecham Corporation	Use of CSAID™ compounds as inhibitors of angiogenesis
US6096748A (en) *	1996-03-13	2000-08-01	Smithkline Beecham Corporation	Pyrimidine compounds useful in treating cytokine mediated diseases
EP0889888A4 (fr)	1996-03-25	2003-01-08	Smithkline Beecham Corp	Nouveau traitement des lesions du systeme nerveux central
EP0889887A4 (fr)	1996-03-25	2003-06-11	Smithkline Beecham Corp	Nouveau traitement de lesions du systeme nerveux central
JP2001511764A (ja)	1996-04-12	2001-08-14	住友製薬株式会社	ピペリジニルピリミジン誘導体
ZA973884B (en) *	1996-05-23	1998-11-06	Du Pont Merck Pharma	Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US6875769B2 (en) *	1996-05-23	2005-04-05	Pfizer Inc.	Substituted6,6-hetero-bicyclicderivatives
BR9710808A (pt)	1996-08-06	1999-08-17	Pfizer	Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
TW477787B (en)	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
US6455690B1 (en)	1996-10-16	2002-09-24	Robert Tam	L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
US6509320B1 (en) *	1996-10-16	2003-01-21	Icn Pharmaceuticals, Inc.	Purine L-nucleosides, analogs and uses thereof
BR9714349A (pt)	1996-10-16	2000-11-14	Icn Pharmaceuticals	L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
WO1998023613A1 (fr)	1996-11-27	1998-06-04	Pfizer Inc.	Derives de pyrimidines bicycliques fusionnes
US6147080A (en)	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
US5929076A (en)	1997-01-10	1999-07-27	Smithkline Beecham Corporation	Cycloalkyl substituted imidazoles
US6268310B1 (en)	1997-01-28	2001-07-31	Nippon Soda Co., Ltd.	Oxazole derivative, process for producing the same, and herbicide
US6498163B1 (en) *	1997-02-05	2002-12-24	Warner-Lambert Company	Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5945422A (en) *	1997-02-05	1999-08-31	Warner-Lambert Company	N-oxides of amino containing pyrido 2,3-D! pyrimidines
WO1998033798A2 (fr)	1997-02-05	1998-08-06	Warner Lambert Company	Pyrido[2,3d]pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire
CA2306077A1 (fr)	1997-10-08	1999-04-15	Smithkline Beecham Corporation	Nouveaux composes substitues de cycloalcenyle
AU1924699A (en)	1997-12-19	1999-07-12	Smithkline Beecham Corporation	Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
US6423695B1 (en)	1998-01-13	2002-07-23	Ribapharm, Inc.	Cytokine related treatments of disease
EA200000840A1 (ru) *	1998-02-17	2001-02-26	Туларик, Инк.	Антивирусные производные пиримидина
US6306866B1 (en)	1998-03-06	2001-10-23	American Cyanamid Company	Use of aryl-substituted pyrimidines as insecticidal and acaricidal agents
JP2000038350A (ja)	1998-05-18	2000-02-08	Yoshitomi Pharmaceut Ind Ltd	糖尿病治療薬
US20040044012A1 (en)	1998-05-26	2004-03-04	Dobrusin Ellen Myra	Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
TR200003429T2 (tr)	1998-05-26	2001-07-23	Warner-Lambert Company	Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.
US6423425B1 (en)	1998-05-26	2002-07-23	Ppg Industries Ohio, Inc.	Article having a chip-resistant electrodeposited coating and a process for forming an electrodeposited coating
US6248225B1 (en) *	1998-05-26	2001-06-19	Ppg Industries Ohio, Inc.	Process for forming a two-coat electrodeposited composite coating the composite coating and chip resistant electrodeposited coating composition
JP2002517486A (ja)	1998-06-12	2002-06-18	バーテックスファーマシューティカルズインコーポレイテッド	ｐ３８のインヒビター
US6184226B1 (en) *	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
JP2002526482A (ja)	1998-09-18	2002-08-20	バーテックスファーマシューティカルズインコーポレイテッド	ｐ３８のインヒビター
ATE232205T1 (de) *	1998-10-01	2003-02-15	Astrazeneca Ab	Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird
WO2000023444A1 (fr)	1998-10-21	2000-04-27	Abbott Laboratories	Composes de 4-aminopyrido[2,3-d]pyrimidine a disubstitution 5,7
HK1041483B (zh)	1998-10-23	2004-12-24	霍夫曼-拉罗奇有限公司	雙環氮雜環
US6358959B1 (en)	1999-01-26	2002-03-19	Merck & Co., Inc.	Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
EP1040831A3 (fr)	1999-04-02	2003-05-02	Pfizer Products Inc.	Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
ES2260033T3 (es)	1999-07-02	2006-11-01	Stuart A. Lipton	Uso de los inhibidores p38 mapk en efermadades oftalmicas.
BR0014041A (pt)	1999-09-17	2003-07-15	Smithkline Beecham Corp	Utilização de csaids em infecção por rinovìrus
MXPA02002938A (es)	1999-09-17	2004-12-06	Abbott Gmbh & Co Kg	Inhibidores de cinasa como agentes agentes terapeuticos.
WO2001042243A2 (fr)	1999-12-08	2001-06-14	Advanced Medicine, Inc.	Inhibiteurs de proteine kinase
EP1743655B1 (fr) *	2000-01-21	2014-06-25	Novartis AG	Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
CA2397961C (fr)	2000-01-25	2008-08-26	Richard John Booth	Inhibiteurs de pyrido[2,3-d]pyrimidine-2,7-diamine kinase
JP2003523358A (ja) *	2000-01-27	2003-08-05	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	神経変性疾患の治療のためのピリドピリミジノン誘導体
AR030053A1 (es) *	2000-03-02	2003-08-13	Smithkline Beecham Corp	1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AP2002002643A0 (en)	2000-03-06	2002-12-31	Warner Lambert Co	5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
AU2002248269A1 (en)	2000-10-19	2002-08-12	Smithkline Beecham Corporation	Use of p38 inhibitors for the treatment of inflammation-enhanced cough
CN100525768C (zh) *	2000-10-23	2009-08-12	史密丝克莱恩比彻姆公司	新化合物
JP2002205986A (ja) *	2000-11-08	2002-07-23	Takeda Chem Ind Ltd	ピリミジン誘導体およびそれを含有する除草剤
JP2004521892A (ja) *	2000-12-20	2004-07-22	メルク　エンド　カムパニー　インコーポレーテッド	（ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤
AU2002258400A1 (en) *	2001-02-16	2002-08-28	Tularik Inc.	Methods of using pyrimidine-based antiviral agents
DE10108481A1 (de) *	2001-02-22	2002-10-24	Bayer Ag	Pyridylpyrimidine
WO2002088079A2 (fr)	2001-05-01	2002-11-07	Bristol-Myers Squibb Company	Inhibiteurs doubles de pde 7 et pde 4
US7105667B2 (en)	2001-05-01	2006-09-12	Bristol-Myers Squibb Co.	Fused heterocyclic compounds and use thereof
CA2450934A1 (fr)	2001-06-19	2002-12-27	Marco Dodier	Inhibiteurs pyrimidine de la phosphodiesterase (pde) 7
PE20030008A1 (es)	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
GB0124941D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
JP4178783B2 (ja)	2001-10-19	2008-11-12	三菱化学株式会社	光学記録媒体
US7019002B2 (en) *	2001-12-11	2006-03-28	Pharmacia & Upjohn, S.P.A.	Pyridopyrimidinones derivatives as telomerase inhibitors
US20040063658A1 (en) *	2002-05-06	2004-04-01	Roberts Christopher Don	Nucleoside derivatives for treating hepatitis C virus infection
ITBO20020304A1 (it)	2002-05-17	2003-11-17	Magneti Marelli Powertrain Spa	Nuovi condotti in materiale polimerico
TW200413381A (en)	2002-11-04	2004-08-01	Hoffmann La Roche	Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
WO2004043367A2 (fr) *	2002-11-06	2004-05-27	Bristol-Myers Squibb Company	Composes heterocycliques fusionnes et leur utilisation
JP2004203751A (ja)	2002-12-24	2004-07-22	Pfizer Inc	置換６，６−ヘテロ二環式誘導体
MXPA05007503A (es) *	2003-01-17	2005-09-21	Warner Lambert Co	Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US7138412B2 (en) *	2003-03-11	2006-11-21	Bristol-Myers Squibb Company	Tetrahydroquinoline derivatives useful as serine protease inhibitors
BRPI0410720A (pt) *	2003-05-27	2006-06-20	Pfizer Prod Inc	quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
CN1894222A (zh)	2003-08-05	2007-01-10	沃泰克斯药物股份有限公司	作为电压门控离子通道抑制剂的稠合嘧啶化合物
DE102004020908A1 (de)	2004-04-28	2005-11-17	Grünenthal GmbH	Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
US7098222B2 (en) *	2004-05-12	2006-08-29	Abbott Laboratories	Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
MY145343A (en)	2005-03-25	2012-01-31	Glaxo Group Ltd	Novel compounds
PE20061193A1 (es)	2005-03-25	2006-12-02	Glaxo Group Ltd	DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
US7423042B2 (en)	2005-03-25	2008-09-09	Glaxo Group Limited	Compounds
US20080096905A1 (en) *	2005-03-25	2008-04-24	Glaxo Group Limited	Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
US20090074676A1 (en)	2005-05-23	2009-03-19	Smithkline Beecham Corporation	Inhibition of p38 MAPK For Treatment Of Obesity
WO2007036791A1 (fr)	2005-09-28	2007-04-05	Ranbaxy Laboratories Limited	Dérivés de pyrido-pyrimidine pouvant être employés en tant qu'agents anti-inflammatoires
EA016945B1 (ru)	2005-10-07	2012-08-30	Экселиксис, Инк.	ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
PE20100743A1 (es)	2005-11-15	2010-11-25	Glaxo Group Ltd	Nuevos procedimientos y formulaciones
US20090170834A1 (en)	2005-12-22	2009-07-02	Prolexys Pharmaceuticals, Inc.	Fused Pyrimidones and Thiopyrimidones, and Uses Thereof
TW200800997A (en)	2006-03-22	2008-01-01	Astrazeneca Ab	Chemical compounds
JP2010510317A (ja)	2006-11-20	2010-04-02	ブリストル−マイヤーズスクイブカンパニー	ジペプチジルペプチダーゼｉｖの阻害剤としての７，８−ジヒドロ−１，６−ナフチリジン−５（６ｈ）−オンおよび関連二環式化合物、および方法
CA2719868A1 (fr)	2008-04-29	2009-11-05	F. Hoffmann-La Roche Ag	Pyrimidinyle pyridones inhibiteurs de jnk

2001
- 2001-10-23 CN CNB018178197A patent/CN100525768C/zh not_active Expired - Fee Related
- 2001-10-23 IL IL15536701A patent/IL155367A0/xx unknown
- 2001-10-23 AU AU2002246855A patent/AU2002246855B2/en not_active Ceased
- 2001-10-23 CZ CZ20031125A patent/CZ20031125A3/cs unknown
- 2001-10-23 HU HU0302274A patent/HU229471B1/hu not_active IP Right Cessation
- 2001-10-23 WO PCT/US2001/050493 patent/WO2002059083A2/fr not_active Ceased
- 2001-10-23 ES ES01994463T patent/ES2372028T3/es not_active Expired - Lifetime
- 2001-10-23 AT AT01994463T patent/ATE521353T1/de active
- 2001-10-23 CA CA2426654A patent/CA2426654C/fr not_active Expired - Fee Related
- 2001-10-23 US US10/399,614 patent/US7323472B2/en not_active Expired - Fee Related
- 2001-10-23 NZ NZ524806A patent/NZ524806A/xx not_active IP Right Cessation
- 2001-10-23 MX MXPA03003612A patent/MXPA03003612A/es active IP Right Grant
- 2001-10-23 BR BR0114829-0A patent/BR0114829A/pt not_active Application Discontinuation
- 2001-10-23 PT PT01994463T patent/PT1333833E/pt unknown
- 2001-10-23 EP EP10180694A patent/EP2404603A1/fr not_active Withdrawn
- 2001-10-23 PL PL36204901A patent/PL362049A1/xx not_active Application Discontinuation
- 2001-10-23 JP JP2002559385A patent/JP4524072B2/ja not_active Expired - Fee Related
- 2001-10-23 KR KR1020037005593A patent/KR100850812B1/ko not_active Expired - Fee Related
- 2001-10-23 EP EP01994463A patent/EP1333833B1/fr not_active Expired - Lifetime
- 2001-10-23 CN CN2006100754682A patent/CN1847229B/zh not_active Expired - Fee Related
- 2001-10-23 DK DK01994463.6T patent/DK1333833T3/da active
2003
- 2003-04-10 IL IL155367A patent/IL155367A/en not_active IP Right Cessation
- 2003-04-22 NO NO20031794A patent/NO326830B1/no not_active IP Right Cessation
- 2003-08-19 US US10/470,629 patent/US7314934B2/en not_active Expired - Fee Related
2004
- 2004-04-06 US US10/819,377 patent/US7314881B2/en not_active Expired - Fee Related
2007
- 2007-08-16 US US11/839,833 patent/US20080033170A1/en not_active Abandoned
- 2007-08-16 US US11/839,834 patent/US20080032969A1/en not_active Abandoned
- 2007-08-16 US US11/839,830 patent/US7759486B2/en not_active Expired - Fee Related
2008
- 2008-06-19 IL IL192338A patent/IL192338A0/en unknown
- 2008-06-19 IL IL192337A patent/IL192337A0/en unknown
- 2008-06-19 IL IL192339A patent/IL192339A0/en unknown
2009
- 2009-07-08 JP JP2009161851A patent/JP2009221233A/ja active Pending
2010
- 2010-03-23 JP JP2010066721A patent/JP2010195795A/ja active Pending
- 2010-08-19 US US12/859,645 patent/US8058282B2/en not_active Expired - Fee Related
- 2010-09-16 US US12/883,718 patent/US20110009625A1/en not_active Abandoned
2011
- 2011-11-23 CY CY20111101140T patent/CY1112100T1/el unknown

Also Published As

Publication number	Publication date
NO326830B1 (no)	2009-02-23
CN1561216A (zh)	2005-01-05
MXPA03003612A (es)	2003-06-19
US8058282B2 (en)	2011-11-15
US20110009625A1 (en)	2011-01-13
CA2426654A1 (fr)	2002-08-01
US20050203109A1 (en)	2005-09-15
HUP0302274A2 (hu)	2003-11-28
NZ524806A (en)	2006-03-31
JP4524072B2 (ja)	2010-08-11
BR0114829A (pt)	2003-09-23
HK1059562A1 (en)	2004-07-09
US7323472B2 (en)	2008-01-29
ATE521353T1 (de)	2011-09-15
US20080033170A1 (en)	2008-02-07
US7314881B2 (en)	2008-01-01
KR20040010548A (ko)	2004-01-31
WO2002059083A3 (fr)	2003-04-10
HUP0302274A3 (en)	2012-12-28
CN100525768C (zh)	2009-08-12
EP1333833A4 (fr)	2007-10-24
CZ20031125A3 (cs)	2003-10-15
CA2426654C (fr)	2010-12-21
NO20031794L (no)	2003-06-23
EP2404603A1 (fr)	2012-01-11
IL192338A0 (en)	2008-12-29
CY1112100T1 (el)	2015-11-04
US20110046109A1 (en)	2011-02-24
US20040209901A1 (en)	2004-10-21
PT1333833E (pt)	2011-12-09
CN1847229B (zh)	2011-05-04
EP1333833B1 (fr)	2011-08-24
HU229471B1 (en)	2014-01-28
DK1333833T3 (da)	2011-12-12
PL362049A1 (en)	2004-10-18
KR100850812B1 (ko)	2008-08-06
IL192339A0 (en)	2008-12-29
JP2004517922A (ja)	2004-06-17
US7759486B2 (en)	2010-07-20
IL192337A0 (en)	2008-12-29
IL155367A (en)	2010-12-30
US7314934B2 (en)	2008-01-01
US20090105478A1 (en)	2009-04-23
CN1847229A (zh)	2006-10-18
JP2009221233A (ja)	2009-10-01
JP2010195795A (ja)	2010-09-09
US20040116697A1 (en)	2004-06-17
US20080032969A1 (en)	2008-02-07
EP1333833A2 (fr)	2003-08-13
AU2002246855B2 (en)	2005-12-22
ES2372028T3 (es)	2012-01-13
NO20031794D0 (no)	2003-04-22
WO2002059083A2 (fr)	2002-08-01

Publication	Publication Date	Title
IL155367A0 (en)	2003-12-23	NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES
MY141144A (en)	2010-03-15	1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
IL144144A0 (en)	2002-05-23	Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
IL125282A (en)	2003-06-24	Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
HUP0204399A3 (en)	2004-11-29	Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
HUP0401292A3 (en)	2011-01-28	Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
MY140398A (en)	2009-12-31	4-AMINO-6-PHENYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES
HUP0303296A3 (en)	2006-04-28	Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours, process for their preparation and pharmaceutical compositions containing them
WO1999038877A3 (fr)	1999-09-30	Derives de 2-(purine-9-yl)-tetrahydrofurane-3,4-diol
HUP0104867A3 (en)	2002-06-28	Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
WO2004073628A3 (fr)	2005-05-12	Nouveaux composes
PL373414A1 (en)	2005-08-22	8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
HUP0301167A3 (en)	2009-12-28	Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
MXPA04000886A (es)	2004-06-03	Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
GEP20033081B (en)	2003-10-27	Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
IL164606A0 (en)	2005-12-18	Novel compounds
HUP0002963A3 (en)	2001-09-28	Use of pyrazolo-[4,3-d] pyrimidinon derivatives for the production of pharmaceutical compositions for treating diseases of the eye field
PL366858A1 (en)	2005-02-07	Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
WO2006110298A3 (fr)	2007-12-13	Nouveaux composes
AU2001290480A1 (en)	2002-04-08	Cyclized benzamide neurokinin antagonists for use in therapy
HUP0401350A3 (en)	2009-03-02	Novel imidazopyridine compounds with therapeutic effect, process for their preparation and pharmaceutical compositions containing them
WO2003063764A3 (fr)	2003-11-20	Derives de pyrazolo[3,4-d]pyrimidin-4-ones substitues en position 6 utiles en tant qu'inhibiteurs de la kinase dependante des cyclines
IL165086A (en)	2011-11-30	Pyridyl cyanoguanidines, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments
AU2003245989A1 (en)	2004-01-23	Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
MXPA03008894A (es)	2003-12-08	Uso de compuestos de imidazo[1,2-a]-piridin-3-il-amidas e imidazo [1,2-a]-piridin-3-il-aminas sustituidas como medicamentos.